IL283414A - Methods of treating conditions related to the s1p1 receptor - Google Patents
Methods of treating conditions related to the s1p1 receptorInfo
- Publication number
- IL283414A IL283414A IL283414A IL28341421A IL283414A IL 283414 A IL283414 A IL 283414A IL 283414 A IL283414 A IL 283414A IL 28341421 A IL28341421 A IL 28341421A IL 283414 A IL283414 A IL 283414A
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- methods
- conditions associated
- treating conditions
- treating
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773936P | 2018-11-30 | 2018-11-30 | |
| US201962850464P | 2019-05-20 | 2019-05-20 | |
| PCT/US2019/063413 WO2020112880A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating conditions related to the s1p1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283414A true IL283414A (en) | 2021-07-29 |
Family
ID=68966033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283414A IL283414A (en) | 2018-11-30 | 2021-05-25 | Methods of treating conditions related to the s1p1 receptor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220023258A1 (https=) |
| EP (1) | EP3886841A1 (https=) |
| JP (2) | JP2022511788A (https=) |
| KR (1) | KR102824401B1 (https=) |
| CN (2) | CN118649163A (https=) |
| AU (1) | AU2019387212A1 (https=) |
| CA (1) | CA3120706A1 (https=) |
| IL (1) | IL283414A (https=) |
| WO (1) | WO2020112880A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| JP5856980B2 (ja) * | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| CN104093310A (zh) * | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2015257589A1 (en) * | 2014-05-09 | 2016-11-24 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| CA3000569A1 (en) * | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| MX2019009841A (es) * | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
-
2019
- 2019-11-26 CN CN202410692934.XA patent/CN118649163A/zh active Pending
- 2019-11-26 US US17/299,741 patent/US20220023258A1/en not_active Abandoned
- 2019-11-26 KR KR1020217019803A patent/KR102824401B1/ko active Active
- 2019-11-26 EP EP19824097.0A patent/EP3886841A1/en active Pending
- 2019-11-26 JP JP2021530816A patent/JP2022511788A/ja not_active Withdrawn
- 2019-11-26 CA CA3120706A patent/CA3120706A1/en active Pending
- 2019-11-26 CN CN201980087042.4A patent/CN113226307A/zh active Pending
- 2019-11-26 WO PCT/US2019/063413 patent/WO2020112880A1/en not_active Ceased
- 2019-11-26 AU AU2019387212A patent/AU2019387212A1/en not_active Abandoned
-
2021
- 2021-05-25 IL IL283414A patent/IL283414A/en unknown
-
2024
- 2024-11-08 JP JP2024195531A patent/JP2025024035A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020112880A1 (en) | 2020-06-04 |
| KR20210098487A (ko) | 2021-08-10 |
| KR102824401B1 (ko) | 2025-06-25 |
| JP2025024035A (ja) | 2025-02-19 |
| CA3120706A1 (en) | 2020-06-04 |
| AU2019387212A1 (en) | 2021-06-24 |
| CN113226307A (zh) | 2021-08-06 |
| CN118649163A (zh) | 2024-09-17 |
| JP2022511788A (ja) | 2022-02-01 |
| EP3886841A1 (en) | 2021-10-06 |
| US20220023258A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280913A (en) | Novel methods | |
| IL283414A (en) | Methods of treating conditions related to the s1p1 receptor | |
| IL280912A (en) | Novel methods | |
| IL255461A (en) | Anti-transferrin receptor antibodies with tailored affinity | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| EP3863043A4 (en) | SUSCEPTOR | |
| DK3242666T5 (da) | Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren | |
| PL3283110T3 (pl) | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) | |
| DK3849537T3 (da) | Kombinationsterapier | |
| EP3763567A4 (en) | SEAT | |
| DK3737403T5 (da) | Modificerede adenovira | |
| IL284114A (en) | Methods of treating conditions related to the s1p1 receptor | |
| PT3579826T (pt) | Métodos de tratamento de distúrbios de cdkl5 com o composto ov329 | |
| EP3843832C0 (en) | NEUROMODULATION SYSTEM | |
| IL279180A (en) | Methods of treating conditions related to the S1P1 receptor | |
| EP3876776C0 (en) | CONNECTOR | |
| IL272163A (en) | Methods of treating myelodysplastic syndrome | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| EP3899155A4 (en) | IMPROVED CONNECTOR | |
| EP3813610A4 (en) | Locking mechanism | |
| DK3617431T3 (da) | Lås | |
| CL2018000754S1 (es) | Cerradura | |
| EP3811824A4 (en) | SEAT | |
| EP3843748C0 (en) | COMBINATION THERAPY | |
| PL3880011T3 (pl) | Sposób |